SCHEMBL2274003

SCHEMBL2274003

COC(=O)c1ccc(-c2ccccc2)cc1NC(=O)c1ccc(OC)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 2/20 0.66
KDM4E B2RXH2 5/20 0.63
ALDH1A1 P00352 3/20 0.63
HPGD P15428 2/20 0.63
POLB P06746 2/20 0.63
ADORA3 P0DMS8 1/20 0.63
F10 P00742 1/20 0.59
MAPT P10636 3/20 0.59
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
HSD17B10 Q99714 2/20 0.57
MAPK1 P28482 1/20 0.57
TSHR P16473 1/20 0.57
PKM P14618 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TRPV1 Q8NER1 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.55
LMNA P02545 1/20 0.55
PRSS12 P56730 1/20 0.54
RAB9A P51151 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269165 0.91 MEN1 (0.69) HDAC2KDM4EALDH1A1HPGDADORA3
SCHEMBL2271167 0.91 KDM4E (0.64) HDAC2KDM4EALDH1A1HPGDMAPT
SCHEMBL12369428 0.89 HDAC2 (0.72) HDAC2KDM4EALDH1A1HPGDPOLB
SCHEMBL14428246 0.89 HDAC1 (0.57) HDAC2KDM4EALDH1A1POLBMAPT
SCHEMBL2275393 0.87 HDAC2 (0.73) HDAC2KDM4EALDH1A1HPGDADORA3
SCHEMBL12369429 0.87 KDM4E (0.60) HDAC2KDM4EALDH1A1HPGDPOLB
SCHEMBL12369435 0.86 HDAC2 (0.67) HDAC2KDM4EALDH1A1HPGDPOLB
SCHEMBL2269238 0.85 KDM4E (0.68) KDM4EALDH1A1HPGDPOLBF10
SCHEMBL4835334 0.85 TSHR (0.58) KDM4EHPGDPOLBMAPTKMT2A
SCHEMBL12395053 0.84 HDAC2 (0.65) HDAC2KDM4EALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 HDAC2 276/4885KDM4E 1257/4885ALDH1A1 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.